Literature DB >> 2104570

Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.

P Sonneveld1, K H Kurth, A Hagemeyer, J Abels.   

Abstract

Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. In one patient, karyotypic abnormalities (-5, 7q-) typical of a therapy induced malignancy were associated with rapid progression of a refractory anemia with excess blasts in transformation to an acute non-lymphocytic leukemia. Intravesical chemotherapy may be associated with a risk of secondary malignancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104570     DOI: 10.1002/1097-0142(19900101)65:1<23::aid-cncr2820650107>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  The effects of thiotepa, mitomycin C, BCG and interferon instillation on urothelium.

Authors:  O Polat; C Gündoğdu; A Demirel; Y Bayraktar; O Gül; M Ozbilge
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.